FACULTY
Jessica R. Allegretti, MD, MPH, FACG, AGAF
Director, Crohn’s and Colitis Center
Division of Gastroenterology, Hepatology and Endoscopy
Brigham and Women’s Hospital
Associate Professor of Medicine, Harvard Medical School
Boston, MA
PROGRAM OVERVIEW
This Educational Snapshot online activity aims to help clinicians better explain the etiopathogenesis of IBD, including the molecular attributes IL-23 and CD64, and how biologics, including IL-23-targeting therapies, take advantage of the Th17 pathway and are becoming a primary component of IBD management. Also to be discussed are strategies to improve patient outcomes, improve medication adherence, and reduce costs. This includes treatment algorithms, shared decision-making (SDM), and tracking symptom response, AEs, and objective endpoints.
TARGET AUDIENCE
This activity is designed to meet the educational needs of gastroenterologists, trainees, advanced practice providers, and other members of the care team to ensure optimal patient outcomes in the management of IBD.
LEARNING OBJECTIVES
- Explain the etiopathogenesis of inflammatory bowel disease (IBD), including the molecular attributes of IL-23 and CD64, and how biologics take advantage of the T helper 17 (Th17) pathway.
- Describe the clinical efficacy and safety profiles of IL-23 targeting therapies for the management of IBD to build treatment algorithms that track symptom response, AEs, and objective endpoints to ultimately improve patient outcomes
- Design a guideline for shared decision-making (SDM) to promote productive conversations with patients, leading to increased medication adherence, lower costs, and improved clinical outcomes
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.50 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty | Relationship | Manufacturer |
| Jessica R. Allegretti, MD, MPH, FACG, AGAF | Consultant | AbbVie, Bristol Myers Squibb, Celltrion, Ferring, GSK, Genentech, Janssen, Merck & Co., Pfizer, Roche, Roivant, Seres Therapeutics, and Vedanta Biosciences |
| Speaker Bureau | AbbVie, Bristol Myers Squibb and Janssen | |
| Contracted Research | AbbVie, Bristol Myers Squibb, Janssen, Roche, Sanofi, and Takeda Pharmaceuticals |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Senior VP of Operations for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- Nicolas Applyrs, Jr, DO, MS, MPH, has nothing to disclose.
- Caitlin Rothermel, MPH, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Russie Allen, Outcomes and Accreditation Manager for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Sr. Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: April 29, 2025
EXPIRATION DATE: April 29, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
